Evidence map›Paper›PMID 39041892›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Personalized Vascularized Models of Breast Cancer Desmoplasia Reveal Biomechanical Determinants of Drug Delivery to the Tumor.

Giovanni S Offeddu, Elena Cambria, Sarah E Shelton, Kristina Haase, Zhengpeng Wan, Luca Possenti, Huu Tuan Nguyen, Mark R Gillrie, Dean Hickman, Charles G Knutson and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Modeling CAF-tumor interactions to overcome therapy resistance.Journal of experimental & clinical cancer research : CR · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giovanni S OffedduDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Elena CambriaDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0001-6896-5421
Sarah E SheltonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Kristina HaaseEuropean Molecular Biology Laboratory, European Molecular Biology Laboratory Barcelona, Barcelona, 08003, Spain.
Zhengpeng WanDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Luca PossentiLaBS, Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Milan, 20133, Italy.
Huu Tuan NguyenDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Mark R GillrieDepartment of Medicine, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, T2N 2T9, Canada.
Dean HickmanAmgen Research, Amgen Inc., 360 Binney Street, Cambridge, MA, 02142, USA.
Charles G KnutsonAmgen Research, Amgen Inc., 360 Binney Street, Cambridge, MA, 02142, USA.
Roger D KammDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID 0000-0002-7232-304X

Funding

Studying E-cadherin dynamics during extravasation and metastatic colonizationU54CA261694 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ROGER D KAMM · 2021 to 2026
$9.1M
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint BlockadeU01CA214381 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BARBIE, DAVID A, KAMM, ROGER D · 2017 to 2021
$3.5M
Imaging Cancer Angiogenesis with Acoustic Angiography UltrasoundK00CA212227 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SHELTON, SARAH ELIZABETH · 2018 to 2021
$392k
American-Italian Cancer FoundationAmgenFondazione AIRC per la ricerca sul cancro ETS IG21479Ludwig Center at MIT Koch Institute for Integrative Cancer ResearchNCI NIH HHS K00 CA212227NCI NIH HHS K00CA212227NCI NIH HHS U01 CA214381NCI NIH HHS U01CA214381NCI NIH HHS U54 CA261694NCI NIH HHS U54CA261694Swiss National Science Foundation P2EZP2_199914Swiss National Science Foundation P500PB_222131Swiss National Science Foundation SNSF-P400PB_186779
6 · The paper itself

Abstract

Desmoplasia in breast cancer leads to heterogeneity in physical properties of the tissue, resulting in disparities in drug delivery and treatment efficacy among patients, thus contributing to high disease mortality. Personalized in vitro breast cancer models hold great promise for high-throughput testing of therapeutic strategies to normalize the aberrant microenvironment in a patient-specific manner. Here, tumoroids assembled from breast cancer cell lines (MCF7, SKBR3, and MDA-MB-468) and patient-derived breast tumor cells (TCs) cultured in microphysiological systems including perfusable microvasculature reproduce key aspects of stromal and vascular dysfunction causing impaired drug delivery. Models containing SKBR3 and MDA-MB-468 tumoroids show higher stromal hyaluronic acid (HA) deposition, vascular permeability, interstitial fluid pressure (IFP), and degradation of vascular HA relative to models containing MCF7 tumoroids or models without tumoroids. Interleukin 8 (IL8) secretion is found responsible for vascular dysfunction and loss of vascular HA. Interventions targeting IL8 or stromal HA normalize vascular permeability, perfusion, and IFP, and ultimately enhance drug delivery and TC death in response to perfusion with trastuzumab and cetuximab. Similar responses are observed in patient-derived models. These microphysiological systems can thus be personalized by using patient-derived cells and can be applied to discover new molecular therapies for the normalization of the tumor microenvironment.

Indexed as

Breast NeoplasmsDrug Delivery SystemsTumor MicroenvironmentCell Line, TumorFemaleHumansHyaluronic AcidPrecision MedicineHyaluronic Acidhyaluronic acidmicrophysiological systemspermeabilityTGFβ mechanotherapytumor vascularizationvascular glycocalyx

Identifiers

PMID39041892
PMCPMC11481247

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.